Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
SEATTLE, WA – Aptevo Therapeutics Inc . (NASDAQ:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, has announced the filing of a prospectus supplement with the Securities and Exchange Commission (SEC) for the offering of its common stock. The company, headquartered in Seattle, Washington, disclosed the potential sale of shares with an aggregate offering price of up to $3,167,548. According to InvestingPro data, Aptevo’s stock currently trades at $0.57, near its 52-week low, with a market capitalization of just $1.81 million. The company’s shares have experienced significant volatility, declining over 94% in the past six months.
The filing, made today, is part of an At The Market Offering Agreement with Roth Capital Partners (WA:CPAP), LLC, dated Sunday, April 28, 2025. This arrangement allows Aptevo to issue and sell its shares from time to time at prevailing market prices. As of today, the company has already sold 305,845 shares of common stock, raising approximately $181,848 in gross proceeds. InvestingPro analysis shows the company maintains a current ratio of 1.72 and holds more cash than debt on its balance sheet, though its overall financial health score remains weak at 1.28 out of 5.
The offering is being made under Aptevo’s existing effective registration statement on Form S-3 and supplements a prospectus filed with the SEC on April 28, 2025. The legal firm Paul Hastings LLP provided a legal opinion regarding the shares, which is included in the SEC filing as an exhibit.
This move comes as part of Aptevo’s strategy to raise capital, potentially providing the company with additional resources to fund its operations and development projects. The sale of shares is subject to market conditions, and no assurance can be given as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Despite the current stock price challenges, analysts maintain a price target of $21, according to InvestingPro, which also indicates the stock is trading below its Fair Value. Subscribers can access 15 additional ProTips and comprehensive financial metrics to better evaluate this investment opportunity.
Investors are directed to the prospectus for details regarding the offering. The SEC filing, including the prospectus supplement and legal opinion, is available for public viewing. It should be noted that this report does not constitute an offer to sell or a solicitation of an offer to buy the described securities, and no sales will be made in jurisdictions where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The information in this article is based on the SEC filing by Aptevo Therapeutics Inc.
In other recent news, Aptevo Therapeutics has announced several financial and developmental activities. The company has entered into an At The Market Offering Agreement with Roth Capital Partners, allowing it to offer and sell shares of its common stock, aiming to raise up to approximately $3 million. Additionally, Aptevo has initiated a registered direct offering of 2,324,000 shares priced at $0.862 per share, expected to raise about $2 million before fees. Another offering involves the sale of 1,764,710 common stock shares and warrants for an anticipated gross proceeds of around $2.1 million. These funds are intended to support the clinical development of Aptevo’s cancer immunotherapy pipeline, including trials for Mipletamig and ALG.APV-527.
The company recently reported advancements in its preclinical compound APVO603, which shows potential in treating solid tumors by targeting specific immune receptors. Aptevo’s pipeline also features other promising candidates like APVO711 and APVO442, indicating ongoing progress in its research and development efforts. The company continues to rely on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms to enhance cancer treatment outcomes. Investors are advised to consider the risks detailed in the company’s SEC filings, as Aptevo’s announcements include forward-looking statements subject to uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.